Expression of Matrix Metalloproteinases and Their Tissue Inhibitors in Peripheral Blood Leukocytes and Plasma of Children with Nonalcoholic Fatty Liver Disease
Open Access
- 10 September 2020
- journal article
- research article
- Published by Wiley in Mediators of Inflammation
- Vol. 2020, 1-14
Abstract
Gene expression profiles of matrix metalloproteinases (MMPs) and their tissue inhibitors (TIMPs) were evaluated in peripheral blood leukocytes of children with nonalcoholic fatty liver disease (NAFLD). Gene expression patterns were correlated with their plasma protein counterparts, systemic parameters of liver injury, and selected markers of inflammation. The MMP-2, MMP-9, MMP-12, MMP-14, TIMP-1, TIMP-2, TGF-β, and IL-6 transcripts levels were tested by the real-time PCR. Plasma concentrations of MMP-9, TIMP-1, MMP-9/TIMP-1 ratio, MMP-2/TIMP-2 ratio, sCD14, leptin, resistin, IL-1 beta, and IL-6 and serum markers of liver injury were estimated by ELISA. The MMP-9, TIMP-2 expression levels, plasma amounts of MMP-9, TIMP-1, and the MMP-9/TIMP-1 ratio were increased in children with NAFLD. Concentrations of AST, ALT, GGT, and leptin were elevated in serum patients with NAFLD, while concentration of other inflammatory or liver injury markers was unchanged. The MMP-2 and MMP-9 levels correlated with serum liver injury parameters (ALT and GGT concentrations, respectively); there were no other correlations between MMP/TIMP gene expression profiles, their plasma counterparts, and serum inflammatory markers. Association of MMP-2 and MMP-9 expression with serum liver injury parameters (ALT, GGT) may suggest leukocyte engagement in the early stages of NAFLD development which possibly precedes subsequent systemic inflammatory responses.Keywords
Funding Information
- Narodowe Centrum Nauki (2011/01/B/NZ6/02661)
This publication has 37 references indexed in Scilit:
- Leukocyte transmigration across endothelial and extracellular matrix protein barriers in liver ischemia/reperfusion injuryCurrent Opinion in Organ Transplantation, 2011
- Inflammatory activation in children with primary hypertensionPediatric Nephrology, 2010
- MMPs as therapeutic targets—Still a viable option?Seminars in Cell & Developmental Biology, 2008
- Metalloproteinase-9 deficiency protects against hepatic ischemia/reperfusion injuryHepatology, 2007
- Differential regulation of matrix metalloproteinase 2 and matrix metalloproteinase 9 by activated protein C: Relevance to inflammation in rheumatoid arthritisArthritis & Rheumatism, 2007
- Bone marrow–derived cells express matrix metalloproteinases and contribute to regression of liver fibrosis in miceHepatology, 2006
- Histopathology of Pediatric Nonalcoholic Fatty Liver Disease * #Hepatology, 2005
- Use and Abuse of HOMA ModelingDiabetes Care, 2004
- Tissue inhibitors of metalloproteinases in liver fibrosisThe International Journal of Biochemistry & Cell Biology, 1997
- Ultrasound scanning in the detection of hepatic fibrosis and steatosis.BMJ, 1986